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INTRODUCTION
Periodontal diseases are a group of chronic 
inϐlammatory diseases that affect the supporting 
tissues of the dentition. Periodontitis is one of the 
most frequent periodontal diseases. It is induced 
by the dental plaque bacteria in association with 
an abnormal host immune response to these 
microorganisms and their products in disease 
susceptible individuals (Machida et al., 2014; Craig 
et al., 2007). It is characterized by gingival bleeding, 
periodontal pocket formation, destruction of 
connective tissue attachment, and alveolar bone 
resorption. In periodontal lesions leukocytes 
produce reactive oxygen species (ROS), as an 
initial host defense against the bacterial pathogens 
(Tomofuji et al., 2011). ROS includes superoxide, 
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Abstract
Between chronic kidney disease and chronic periodontitis there is bilateral relationship. The aim of the study 
was to assess the salivary nitro-oxidative stress and matrix metallopeoteinase-9 in chronic periodontitis and 
chronic kidney disease with chronic periodontitis. Eligible participants were categorized into three categories: 
healthy controls, chronic periodontitis and chronic kidney disease with chronic periodontitis. Periodontal status 
was assessed using probing depths, bleeding on probing, and clinical attachment level loss.  The chronic kidney 
disease was diagnosed using the level of estimated glomerular ϐiltration rate. From the saliva were assessed nitro-
oxidative stress biomarkers (total nitrites and nitrates, total oxidative status, total antioxidant reactivity, and 
oxidative stress index) and matrix metallopeoteinase-9. In both disease groups there was a signiϐicant increase 
in saliva nitro-oxidative stress due to an increased nitric oxide and reactive oxygen species formation (p<0.001) 
without a signiϐicant change of the antioxidants (p>0.05) and a concomitant increase of matrix metallopeoteinase-9 
(p<0.001). However, no statistically signiϐicant difference was observed (p>0.05) when the intergroup comparison 
were made among the chronic periodontitis and chronic kidney disease with chronic periodontitis. Conclusions: 
Saliva nitro-oxidative stress markers and matrix metallopeoteinase-9 may be useful tests for pathogenetic and 
prognostic diagnosis in chronic periodontitis and chronic kidney disease with chronic periodontitis.
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hydroxyl, and nitric oxide radical species, as well 
as nonradical derivatives of oxygen. Excessive 
production of ROS disrupts the tissue oxidative/
antioxidative balance, and induces oxidative 
injury by damaging DNA, lipids, and proteins. 
Clinical studies have found that periodontitis 
patients have high blood levels of ROS compared 
to periodontally healthy subjects (Machida et 
al., 2014; Pârvu et al., 2013). Furthermore, it 
has been shown that periodontal treatment and 
some systemic treatments may decrease ROS in 
chronic periodontitis patients (Pârvu et al., 2014). 
Although it is still unclear whether oxidative status 
is the cause or result of periodontitis, it has been 
suggested that systemic oxidative stress can affect 
periodontitis progression, and may be a risk factor 
for systemic diseases, including diabetes mellitus, 
cardiovascular diseases, liver diseases, preterm 
low birth weight, hepatocellular carcinoma, and 
chronic kidney disease (CKD). Furthermore, 
mediators from systemic sources may amplify the 
local periodontal inϐlammatory cascade, but do 
not cause periodontitis by themselves (Ardalan et 
al., 2011; Wehmeyer et al., 2013; Pizzo et al., 2010; 
Graziani et al., 2010; Offenbacher, 1996). 
More and more epidemiologic data support 
an association between periodontitis and chronic 
kidney disease (CKD) (Shaqman et al., 2010; 
Grubbs et al., 2011; Ismail et al., 2013). Compared 
to individuals with normal kidney function, 
individuals with reduced kidney function had 
higher prevalence of periodontitis (Ioannidou 
et al., 2013). CKD is a clinical syndrome induced 
by the progressive and irreversible loss of the 
glomerular ϐiltration rate (Luczyszyn et al., 
2012). CKD patients are characterized by a 
uremic milieu, which has been associated with 
immunosuppression (Ioannidou et al., 2011a; 
Ioannidou et al., 2014). Disturbances of the 
immune system in CKD involve both innate and 
adaptive immunity (Kato et al., 2008). Functional 
abnormalities of monocytes, neutrophils, and 
dendritic cells, impaired maturation of Th 
lymphocytes are directly linked to infection risk in 
this patient population (Anding et al., 2003; Ando 
et al., 2005; Carracedo et al., 2006). CKD may be 
associated with several oral manifestations, such 
as xerostomia, uremic stomatitis and periodontitis 
(Luczyszyn et al., 2012). In CKD patients salivary 
cytokines and secretion rates are signiϐicantly 
decreased (Thorman et al., 2010). Structural 
equation models exploring the bidirectional 
relationship of CKD and periodontitis suggested 
that CKD may have direct effect on moderate 
periodontitis, and that individuals with moderate 
periodontitis were more likely to have CKD 
(Ioannidou et al., 2011b; Pradeep et al., 2012; Dağ 
et al., 2010; Huang et al., 2014).
MMP-9 is a multidomain enzyme functioning 
in acute and chronic inϐlammatory diseases. 
It is mainly secreted by neutrophils although 
macrophages, T cells, mast cells, and odontoblasts 
can also express this enzyme.  MMP-9 is essential 
for initiating the osteoclastic resorption process. 
In periodontitis, the expression of MMP-9 is found 
to be signiϐicantly higher than that in normal 
periodontal tissue (Wan et al., 2014).
The data on MMP-9 concentrations in CKD 
patients are scarce and contradictory and concern 
only adults (Musiał et al., 2010).
Local and systemic enhanced nitro-oxidative 
stress and MMP-9 in patients with CP were 
conϐirmed in saliva, GCF and plasma (Roberts 
et al., 2009; Roberts et al., 2010). A positive 
association between nitro-oxidative stress, MMP-
9 and chronic kidney disease (CKD) has been also 
reported. However, the effects of CKD association 
with periodontitis on saliva nitro-oxidative stress 
and MMP-9 are unknown. Therefore, the aim 
of our study was to evaluate the nitro-oxidative 
stress and the levels of MMP-9 in saliva samples 




Creatinine kit (AMEDA Labordiagnostik GmbH, 
Graz, Austria), and MMP-9 (gelatinase B) ELISA 
kits (R&D Systems, Abingdon, UK), sulfanilamide 
(SULF), N-(1-Naphthyl) ethylendiamine dihydro-
chloride (NEDD), Vanadium (III) chloride 
(VCl
3
) methanol, diethylether, xylenol orange 
[o-cresosulfonphthalein-3,3-bis (sodium methy-
limi no diacetate)], ortho dianisidine dihydro-
chlo ride (3-3′-dimethoxybenzidine), ferrous 





sul furic acid, hydrochloride acid, glycerol, and 
trolox (6-hydroxy-2,5,7,8-tetramethylchroman-
2-carboxylic acid) were purchased from Merck 
(Darmstadt, Germany) and Sigma-Aldrich 
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about the study and invited to participate. 
Written informed consent was obtained from 
all study participants before clinical periodontal 
examination and blood sampling.
This study protocol involved human subjects, 
and as such was reviewed and approved by the 
ethics committees of the University of Medicine and 
Pharmacy Iuliu Hatieganu Cluj-Napoca (Romania), 
and the Faculty of Medicine and Pharmacy, Oradea 
(Romania). The study was conducted according to 
the principles outlined in the Declaration of Helsinki 
on experimentation involving human subjects.
Blood and saliva sampling
Fasting venous blood samples were collected. 
Blood was processed into serum within 2 h 
after collection: whole blood was kept at room 
temperature for 30–45 min to allow a clot to form, 
and then centrifuged (1500 g) for 12 min to collect 
the serum. Whole saliva samples were obtained 
before clinical periodontal measurements and 
any periodontal intervention by having patients 
expectorate into polypropylene tubes in the 
morning following an overnight fast during which 
subjects were requested not to drink (except 
water) or chew gum. The saliva samples were 
centrifuged (800 g) for 10 min at +4°C. The serum 
and saliva samples were assayed immediately or 
frozen at -40 °C for biochemical tests and at -20 
°C for enzyme-linked immunosorbent assays 
(ELISAs), and thawed immediately before assays. 
Evaluation of renal function
Serum creatinine (Scr) level was determined 
according to the manufacturer’s instructions. The 
new guideline recommended using eGFR based on 
Scr level for initial renal function assessment. eGFR 
was calculated using the simpliϐied Modiϐication of 
Diet in Renal Disease (MDRD) formula (eGFR=186 
× [Scr/88,4] −1.154 × [Age ]−0.203 × [0.742 if Female]), 
where Scr is in micromoles/L,  88.4 is the 
molecular weight of Scr and age is stated in years. 
We used the modiϐied National Kidney Foundation 
classiϐication of CKD, which classiϐies eGFR into 
the following ranges: more than 90 mL/min/1.73 
m2 stage 1; 60 to 89 mL/min/1.73 m2 stage 2; 45 
to 59 mL/min/1.73 m2 stage 3a; 30 to 44 mL/
min/1.73 m2 stage 3b; 15 to 29 mL/min/1.73 m2 
stage 4; and less than 15 mL/min/1.73 m2 stage 
5 (Redal-Baigorri et al., 2013; Levey  et al., 2014).
Evaluation of NO synthesis 
NO synthesis was evaluated indirectly by 
measuring serum levels of nitrites and nitrates 
Study design and population
This was a prospective exploratory study that 
included 3 visits, randomized between January 
2010 and December 2013. Test groups consisting 
of healthy controls (HC), patients with untreated 
chronic periodontitis (CP), or with CKD and CP 
(CKD-CP), were recruited from the Department 
of Periodontology, University of Medicine and 
Pharmacy Iuliu Hatieganu, Cluj Napoca (Romania) 
and the County Emergency Clinical Hospital Oradea, 
(Romania). Patient eligibility was evaluated during 
the ϐirst visit. At the ϐirst visit patients’ medical and 
dental histories were obtained, and the patients 
underwent clinical and radiographic evaluation 
in order to diagnose periodontal disease. The 
CP group inclusion criteria were as follows: age, 
30–60 years; at least 16 teeth present; at least 3 
teeth in the same sextant; diagnosis of moderate 
to advanced chronic periodontitis; at least 2 
sites with probing depths (PD) ≥5 mm together 
with bleeding on probing (BOP); ≥5-mm clinical 
attachment level (CAL) loss; and radiographic 
evidence of alveolar bone height loss (4). At 
the second visit, blood samples were collected 
to assess renal function. The CKD criteria were 
deϐined according to clinical practice guidelines, 
using the level of estimated glomerular ϐiltration 
rate (eGFR) (Redal-Baigorri et al., 2013; Levey  et 
al., 2014). Patients were excluded according to the 
following criteria: younger than 30 years and older 
than 70 years; receiving any pharmacological 
treatment within the 3 months before the 
beginning of the study;  had already been treated 
for periodontal disease in the previous 6 months; 
clinically signiϐicant or unstable organic diseases 
other than CKD; compromised healing potential, 
such as connective tissue disorders or bone 
metabolic diseases; females who were pregnant 
or lactating, or who were of childbearing potential 
and not utilizing birth control or abstinence; 
cigarette smokers; active infectious diseases; and 
immunocompromised patients or those taking 
steroid medications. Finally, eligible participants (n 
= 168) were categorized into 3 mutually exclusive 
categories (n = 56/group): HC, CP, and CKD with 
CP (CKD-CP). The selection for this study was 
randomized by age and gender matching. At the 
third visit saliva samples were collected to assess 
local nitro-oxidative stress and MMP-9 levels. 
Every subject who fulϐilled the inclusion 
criteria was provided with detailed information 
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(NOx). First, serum samples were passed through 10-
kDa ϐilters (Sartorius AG, Goettingen, Germany) and 
contaminant proteins were removed by extraction 
with a 3:1 (v:v) solution of methanol/diethyl ether. 
The methanol/diethyl ether ratio in samples was 1:9 
(v:v) (Harma  et al., 2003). The Griess reaction was 
used to determine the levels of nitrites and nitrates 
(NO
x
) indirectly. In brief, 100 μL of 8 mg/mL VCl
3
 
was added to 100 μL of ϐiltered and extracted serum 
supernatant to reduce nitrates to nitrites, followed 
by addition of Griess reagents, 50 μL of sulfanilamide 
(2%) and 50 μL of N-(L-naphthyl) ethylenediamine 
dihydrochloride (0.1%). After incubation for 30 min 
at 37°C, absorbance in the sample was read at 540 
nm. NO
x
 concentration in serum was determined 
using a sodium nitrite-based curve, and expressed as 
μmol/L of nitrite (Miranda et al., 2001).
Evaluation of oxidative stress 
The total oxidative status (TOS) of the serum 
was measured using a colorimetric assay (Erel, 
2005). This assay measured oxidation of the 
ferrous ion to the ferric ion in the presence of 
various ROS in an acidic medium. The ferric ion 
was detected by its reaction with xylenol orange. 





 as the oxidative species. Assay results are 





Total antioxidant reactivity (TAR) in the serum 
was measured using a colorimetric assay (Erel, 
2004). This assay measured the rate of production 
of hydroxyl radicals by the Fenton reaction, 
which was monitored by following changes in the 
absorbance of colored dianisidyl radicals. Upon 
addition of a serum sample, hydroxyl radical-
initiated oxidative reactions were suppressed by 
antioxidants in the serum. Inhibition of dianisidyl 
oxidation prevented the subsequent color change, 
thereby enabling measurement of the total 
antioxidant capacity of the serum. This assay was 
calibrated using trolox, and results expressed as 
mmol trolox equiv/L.
The ratio of TOS to TAR represents oxidative 
stress index (OSI), an indicator of the degree of 
oxidative stress (Harma  et al., 2003), and is given 
by the formula: 




 equiv/L) / 
TAR (mmol trolox equiv/L).
Evaluation of MMP-9
Because circulating levels of MMPs presuma-
bly reϐlect their expression level, serum concen-
trations of MMP-9 (gelatinase B) were evaluated 
by ELISA kits (R&D Systems, Abingdon, UK). 
Measurements were performed according to 
the manufacturer’s instructions. Results were 
calculated by reference to standard curves, and 
expressed as MMP-9 ng/mL (Musial  et al., 2011).
Statistical analyses
Continuous normally distributed variables 
were reported as mean and standard deviation 
(SD). Median and inter-quartile ranges were 
used to describe non-normally distributed and 
percentage data. For multiple group comparisons, 
one-way ANOVA was used, as appropriate. 
Posthoc analysis was performed using the Tukey 
or Bonferroni-Holm tests with least signiϐicant 
difference. Variables not normally distributed 
were logarithmically transformed before being 
used in parametric comparative analysis. Pearson’s 
and Spearman’s correlation analyses were used 
to calculate relationships between parameters. 
Signiϐicance was attributed when p < 0.05. All 
statistical analyses were performed using the 
Statistical Package for the Social Science, version 
16.0 (SPSS Inc., Chicago, IL).
RESULTS AND DISCUSSIONS
ROS and MMP-9 are produced during 
periodontal inϐlammation and tissue destruction. 
The main ϐinding of this study was that in CP and 
CKD-CP patients the salivary nitro-oxidative stress 
markers and MMP-9 concentration were increased 
and correlated with the clinical periodontal indices. 
Furthermore, none of the biochemical parameters 
analyzed in saliva revealed statistically signiϐicant 
differences between the two periodontitis groups. 
The observation of the present study is preliminary. 
The results are based on the comparison between 
the three selected groups, each of 56 individuals. 
This limits the generalization of the results, which 
should be veriϐied in a larger population with 
periodontal diseases.
It is known that individuals have great 
differences in their rates of disease progression. 
One objective of periodontal research is to develop 
diagnostic tests to detect metabolic alterations 
that occur in the initial phase of periodontal 
disease (Gonçalves et al., 2009).
Among the 168 eligible participants, clinical 
diagnoses were made and three mutually exclusive 
patient groups were categorized. Demographic 
characteristics of HC, CP and CKD-CP patients are 
DALAI et al
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shown in Table 1. Subjects within groups were 
generally well matched. 
eGFR levels of individuals in the HC and CP 
groups were higher than 90 mL/min/1.73 m2. In 
the CKD-CP group, eGFR was signiϐicantly lower 
than in the HC and CP groups (p < 0.0001). All CKD-
CP patients were in CKD stage 3 (3a/3b = 26/30) 
(Table 1). The factors causing CKD were: chronic 
glomerulonephritis, chronic pyelonephritis, reϐlux 
nephropathy, and polycystic kidney disease. 
Periodontal clinical measurements showed 
signiϐicantly higher values of PD (p < 0.0001), BOP 
(p < 0.0001), and CAL (p < 0.0001) in CP and CKD-
CP groups compared to HC group (Table 1). There 
were no differences in the periodontal clinical 
indices PD (p = 0.19) and BOP (p = 0.10) between 
the CP and CKD-CP groups. Only the CAL (p = 0.03) 
score was lower in the CKD-CP group than in the 
CP group (Table 1).
The use of saliva as sampling material has 
the advantages of being an easy and noninvasive 
collection. The wide diversity of biochemical 
constituents of the human saliva makes it suitable 
to be used as a biological ϐluid of diagnosis value. 
Furthermore, any alternation of biochemical 
markers of the salivary ϐluid could be related to a 
local periodontal disorder or to a systemic disease 
associated with periodontal disorders. That is why 
saliva may offer the basis for a patient speciϐic 
diagnostic test for periodontitis (Gonçalves et al., 
2009). 
In inϐlammatory diseases, under conditions 
of high and sustained NO production, reactive 
nitrogen oxide species (RNS) are formed through 
reaction with reactive oxygen species (ROS) 
(Chapple et al., 2007). NO is produced in vivo 
from L-arginine by nitric oxide synthase (NOS). 
The inducible NOS (iNOS/NOS2) is expressed in 
response to inϐlammatory stimuli, by various cells. 
RNS may induce nitrosative and oxidative stress. 
Nitrosative stress occurs when intermediates are 
produced from nitrosated thiol, hydroxy and amine 
groups (Schieber and Chandel, 2014). Oxidative 
chemistry mediated by RNS is mediated primarily 
by two nitrogen oxide species, peroxynitrite 
(ONOO−) and nitroxyl (NO−). Peroxynitrite 
originates from the reaction between NO and O2−, 
while NO− can result from a variety of chemical 
pathways (Chev et al., 2014).
CKD patients have higher levels of traditional 
systemic inϐlammatory markers, like IL-6, and 
C-reactive protein. Many studies have reported 
increased prevalence and severity of periodontal 
disease in patients with CKD (Jain and Kabi, 
2013). Free radicals are mostly involved in the 
destruction of periodontium during various stages 
of inϐlammatory periodontal diseases. That is why 
the nitro-oxidative stress from CKD may be a 
pathogenetic mechanism for CP and may become 
a therapeutic target in those individuals. When CP 
were compared to HC, a number of alternations 
have been reported in their salivary biomarkers 
(Paknjad and Rezaei, 2013). The saliva NOx levels 
were signiϐicantly higher in CP (p > 0.001) and 
CKD-CP (p = 0.002) patients than in the HC group. 
Between the CP and CKD-CP groups there was 
no signiϐicant difference (p > 0.05) in salivary NO 
synthesis (Table 2). Compared to the HC group, the 
CP (p < 0.01) and CKD-CP (p < 0.001) groups had 
signiϐicantly increased saliva TOS levels (Table 2). 
CP and CKD-CP had similar effects on saliva TOS 
production (p > 0.05). Salivary NO synthesis was 
positively correlated to salivary levels of TOS in 
CP (r = 0.74) and CKD-CP (r = 0.91) patients. The 
interesting ϐinding was that CP did not aggravate 
the nitro-oxidative stress from the CKD. Salivary 
Tab. 1. Demographic characteristics. 
Parameter HC CP CKD-CP
n = 56 56 56










Results are given as mean ± SD; HC, healthy control patients; CP, chronic periodontitis patients; CKD-CP, chronic kidney disease patients with 
chronic periodontitis.
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cytokines and secretion rates are signiϐicantly 
decreased in CKD (Thorman et al., 2014). That may 
be an explanation for the fact that there was no 
signiϐicant difference between the nitro-oxidative 
stress levels in CP and CKD-CP patients.
Antioxidant molecules balance the harmful 
effects of nitro-oxidative stress. There are enzy-
matic and non-enzymatic antioxidants. Antioxi-
dant enzymes, including superoxide dismutase 
and glutathione peroxidase, are less likely to act 
as antioxidant in extracellular ϐluid. This is mostly 
due to their high molecular weights, which do 
not allow them to pass the membrane without 
a structural change. It is expected that non-
enzymatic antioxidants, that have lower molecular 
weights, scavenge ROS in the outer cell matrix 
(Paknjad and Rezaei, 2013). Currently there are no 
gold standard methods for measuring antioxidant 
capacity in human (Palmieri and Sblendorio, 
2010). Assays of total antioxidant capacity like 
TAR have been developed in the place of individual 
antioxidant determination (Erel, 2004). 
The systemic antioxidant systems are severely 
impaired in CP and CKD patients, and worsen 
progressively with the degree of disease (Ismail et 
al., 2013). The saliva TAR levels were insigniϐicantly 
changed in both CP and CKD-CP groups (p > 0.05) 
(Table 2). The saliva OSI values were signiϐicantly 
increased in the CP (p < 0.001) and CKD-CP (p < 
0.001) patients (Table 2), and positively correlated 
with TOS, NOx and the clinical periodontal indices. 
That makes TAR a less useful salivary marker for 
nitro-oxidative stress evaluation in CKD-CP.
Matrix metalloproteinases (MMPs) are zinc-
dependent endopeptidases that participate in 
the degradation of many components of the 
extracellular matrix (ECM). They also catalyze the 
activation reaction of osteoclasts. A special type of 
this group, MMP-9, is expressed by keratinocytes, 
ϐibroblasts, osteoclasts and macrophages. This 
isozyme is responsible for degrading a variety of 
the ECM during physiological and pathological 
conditions (Marcaccini et al., 2009). The severity 
of periodontitis may be associated with increased 
metalloproteinase activity. 
Higher levels of MMP were found in ϐluids and 
gingival tissues from CP patients (Luczyszyn et al., 
2012, Marcaccini et al., 2009). The data on systemic 
MMP-9 concentrations in CKD patients are scarce 
and contradictory (Gonçalves et al., 2009). Some 
studies found decreased levels of MMP-9, whereas 
others noticed no difference between controls and 
CKD patients (Chang et al., 2006; Tsai et al., 2012; 
Pawlak et al., 2011). In another study a gradual 
MMP-9 increase was observed, together with an 
inverse correlation to GFR values (Musiał and 
Zwolińska, 2011). Up to now, saliva MMP-9 was 
not evaluated in CKD-CP patients. In the present 
study the saliva MMP-9 levels were higher in 
CP (p < 0.001) and CKD-CP (p < 0.001) patients 
compared to the HC patients. There was no 
signiϐicant difference between the salivary MMP-
Tab. 2. Periodontal clinical indices, renal function evaluation, and salivary parameters 
Parameter HC CP CKD-CP
PD (mm) 1,43 ± 0,07 6,18 ± 0,05 5,82 ± 0,56
BOP (%) 5,1 ± 0,25 66 ± 2,91 60,6 ± 5,98
CAL (mm) 1,4 ± 0,62 7,5 ± 0,79 6,92 ± 0,65
eGRF (mL/min/1.73 m2) 111,16 ± 10,54 111,29 ± 9,83 45,46 ± 4,87
NOx (μmole/L) 25,47 ± 14,32 48,06 ± 2,15 44,29 ± 17,73
TOS (μmole H2O2 Equiv./L) 15,44 ± 3,05 30,72 ± 15,50 26,08 ± 9,86
TAR (mmole TROLOX Equiv./L) 1,09 ± 0,01 1,09 ± 0,01 1,10 ± 0,01
OSI (AU) 9,75 ± 2,93 20,82 ± 9,84 32,21 ± 6,36
MMP-9 (ng/mL) 56,14 ± 2,48 67,57 ± 1,90 64,43 ± 3,37
Results are given as mean ± SD; HC, healthy control patients; CP, chronic periodontitis patients; CKD-CP, chronic kidney disease patients with 
chronic periodontitis; PD, probing depths; BOP, bleeding on probing; CAL, clinical attachment level; eGFR, estimated glomerular ϐiltration rate.
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9 levels of CP and CKD-CP patients (p > 0.5) (Table 
2). Moreover, MMP-9 changes correlated with the 
clinical periodontal indices, suggesting that MMP-
9 plays an important role in tissue injury from CP 
as well in CKD-CP.
CONCLUSION
The change in the salivary parameters 
analyzed in this study support the hypothesis that 
saliva nitro-oxidative stress markers and MMP-9 
may be used as pathogenetic and prognostic tests 
in both CP and CKD-CP patients. These ϐindings 
of signiϐicantly increased salivary concentrations 
of nitro-oxidative stress markers and MMP-
9 together with signiϐicant worsening of the 
periodontal clinical indices in CP and CKD-CP 
patients deserve further investigation.
Acknowledgements. This work was ϐinancially 
supported by the Ministry of Education, Research 
and Youth, CNCSIS grant PNII-IDEI 1273/2008. 
We would like to thank to Synevo Romania Srl for 
blood samples collection.
Author Disclosure Statement. The authors sta-
te that they have no conϐlict of interest.
REFERENCES
1. Anding K, Gross P, Rost JM, Allgaier D, Jacobs E (2003). The 
inϐluence of uraemia and haemodialysis on neutrophil 
phagocytosis and antimicrobial killing. Nephrol Dial 
Transplant 18:2067-2073.
2. Ando M, Shibuya A, Yasuda M, Azuma N, Tsuchiya K, Akiba 
T, et al. (2005). Impairment of innate cellular response 
to in vitro stimuli in patients on continuous ambulatory 
peritoneal dialysis. Nephrol Dial Transplant 20:2497-
2503.
3. Ardalan MR, Ghabili K, Pourabbas R, Shoja MM (2011). 
A causative link between periodontal disease and 
glomerulonephritis: a preliminary study. Ther Clin Risk 
Manag 7:93-98. 
4. Carracedo J, Merino A, Nogueras S, Carretero D, Berdud I, 
Ramirez R, et al (2006). On-line hemodiaϐiltration reduces 
the proinϐlammatory CD14+CD16+ monocyte-derived 
dendritic cells: a prospective, crossover study. J Am Soc 
Nephrol 17:2315-2321.
5. Chang HR, Yang SF, Li ML, Lin CC, Hsieh YS, Lian JD 
(2006). Relationships between circulating matrix 
metalloproteinase-2 and -9 and renal function in patients 
with chronic kidney disease. Clin Chim Acta 366(1-2): 
243-248.
6. Chapple ILC, Matthews JB (2007). The role of reactive 
oxygen and antioxidant species in periodontal tissue 
destruction, Periodontology 2000 43: 160–232.
7. Chen X, Chen H, Deng R, Shen J (2014). Pros and cons of 
current approaches for detecting peroxynitrite and their 
applications. Biomed J 37(3):120-126. 
8. Craig RG, Kotanko P, Kamer AR, Levin NW (2007). Periodontal 
diseases-a modiϐiable source of systemic inϐlammation for 
the endstage renal disease patient on haemodia-
lysis therapy? Nephrol Dial Transplant  22(2):312-315.
9. Dağ A, Firat ET, Kadiroğlu AK, Kale E, Yilmaz ME (2010). 
Signiϐicance of elevated gingival crevicular ϐluid tumor 
necrosis factor-alpha and interleukin-8 levels in chronic 
hemodialysis patients with periodontal disease. J 
Periodontal Res 45(4):445-450.
10. Erel O (2004). A novel automated method to measure 
total antioxidant response against potent free radical 
reactions. Clin Biochem 37: 112-119.
11. Erel O (2005). A new automated colorimetric method for 
measuring total oxidant status. Clin Biochem 38: 1103-
1111. 
12. Gonçalves RP, Damante CA, Lima FLM, Imbronito AV, 
Nunes FD, Pustiglioni FE (2009). Detection of MMP-
2 and MMP-9 salivary levels in patients with chronic 
periodontitis before and after periodontal treatment. Rev. 
odonto ciênc 24(3):264-269.
13. Graziani F, Cei S, La Ferla F, Vano M, Gabriele M, Tonetti 
M (2010). Effects of non-surgical periodontal therapy on 
glomerular ϐiltration rate of the kidney: an exploratory 
trial. J Clin Periodontol 37: 638–643.
14. Grubbs V, Plantinga LC, Crews DC, Bibbins-Domingo K, 
Saran R, Heung M, et al. (2011). Vulnerable populations 
and the association between periodontal and chronic 
kidney disease. Clin J Am Soc Nephrol 6(4):711-717.
15. Harma M, Harma M, Erel O (2003). Increased oxidative 
stress in patients with hydatidiform mole. Swiss Med Wkly 
133: 563-566.
16. Huang R-Y, Lin Y-F, Kao S-Y, Shieh Y-S, Chen J-S (2014). A 
Retrospective Case-Control Analysis of the Outpatient 
Expenditures for Western Medicine and Dental Treatment 
Modalities in CKD Patients in Taiwan. PLoS ONE 9(2): 
e88418.
17. Ioannidou E, Hall Y, Swede H, Himmelfarb J (2013). 
Periodontitis associated with chronic kidney disease 
among Mexican Americans. J Public Health Dent. 
73(2):112-129.
18. Ioannidou E, Swede H, Dongari-Bagtzoglou A (2011). 
Periodontitis predicts elevated C-reactive protein levels 
in chronic kidney disease. J Dent Res 90(12):1411-1415.
19. Ioannidou E, Swede H, Fares G, Himmelfarb J (2014). 
Tooth loss strongly associates with malnutrition in 
chronic kidney disease. J Periodontol 85(7):899-907. 
20. Ioannidou E, Swede H (2011).  Disparities in periodontitis 
prevalence among chronic kidney disease patients. J Dent 
Res 90(6):730-734.
21. Ismail G, Dumitriu HT, Dumitriu AS, Ismail FB (2013). 
Periodontal Disease: A Covert Source of Inϐlammation in 
Chronic Kidney Disease Patients. Int J Nephrol Article ID 
515796.
Salivary Nitro-Oxidative Stress and Matrix Metalloproteinase-9 in Chronic Kidney Disease with Periodontitis
328
Bulletin UASVM Veterinary Medicine 71 (2) / 2014
22. Jain A, Kabi D (2013). Severe periodontitis associated 
with chronic kidney disease. J Indian Soc Periodontol 
17:128-130. 
23. Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo 
S, Yuzawa Y, et al. (2008). Aspects of immune dysfunction 
in end-stage renal disease. Clin J Am Soc Nephrol 3:1526-
1533. 
24. Levey AS, Inker LA, Coresh J (2014). GFR estimation: from 
physiology to public health. Am J Kidney Dis 63(5): 820-
834. 
25. Luczyszyn SM, de Souza CM, Braosi AP, Dirschnabel AJ, 
Claudino M, Repeke CE, et al. (2012). Analysis of the 
association of an MMP1 promoter polymorphism and 
transcript levels with chronic periodontitis and end-stage 
renal disease in a Brazilian population. Arch Oral Biol 
57(7):954-963. 
26. Machida T, Tomofuji T, Ekuni D, Yamane M, Yoneda T, 
Kawabata Y, et al. (2014). Longitudinal relationship 
between plasma reactive oxygen metabolites and 
periodontal condition in the maintenance phase of 
periodontal treatment. Dis Markers 489292. 
27. Marcaccini AM, Novaes AB Jr, Meschiari CA,  Souza 
SL, Palioto DB, Sorgi CA, et al. (2009). Circulating matrix 
metalloproteinase-8 (MMP-8) and MMP-9 are increased 
in chronic periodontal disease and decrease after non-
surgical periodontal therapy. Clin Chim Acta  409(1-
2):117-122. 
28. Miranda KM, Espey MG, Wink DA (2001). A rapid, simple 
spectrophotometric method for simultaneous detection 
of nitrate and nitrite. Nitric Oxide 5: 62–71. 
29. Musiał K, Zwolińska D (2011). Matrix metalloproteinases 
(MMP-2,9) and their tissue inhibitors (TIMP-1,2) as novel 
markers of stress response and atherogenesis in children 
with chronic kidney disease (CKD) on conservative 
treatment. Cell Stress Chaperones 16(1):97-103. 
30. Offenbacher S (1996). Periodontal diseases: pathogenesis. 
Ann Periodontol 1:821–878.
31. Paknjad M, Rezaei A (2013). Salivary biochemical markers 
of periodontitis. Rom J Biochem 50(2):129–146.
32. Palmieri B, Sblendorio V (2010). Current status of 
measuring oxidative stress. Methods Mol Biol 594: 3-17. 
33. Pârvu AE, Alb SF, Crăciun A, Taulescu MA (2013). Efϐicacy 
of subantimicrobial-dose doxycycline against nitrosative 
stress in chronic periodontitis. Acta Pharmacol Sin 34(2): 
247-254. 
34. Pârvu AE, Tălu S, Crăciun C, Alb SF (2014). Evaluation 
of scaling and root planing effect in generalized chronic 
periodontitis by fractal and multifractal analysis. J Period 
Res  49(2):186-196.  
35. Pawlak K, Mysliwiec M, Pawlak D (2011). Peripheral blood 
level alterations of MMP-2 and MMP-9 in patients with 
chronic kidney disease on conservative treatment and on 
hemodialysis. Clin Biochem 44(10-11):838-843. 
36. Pizzo G, Guiglia R, Lo Russo L, Campisi G (2010). Dentistry 
and internal medicine: from the focal infection theory 
to the periodontal medicine concept. Eur J Intern Med 
21(6):496-502. 
37. Pradeep AR, Kathariya R, Arjun Raju P, Sushma Rani 
R, Sharma A, Raghavendra NM (2012). Risk factors for 
chronic kidney diseases may include periodontal diseases, 
as estimated by the correlations of plasma pentraxin-3 
levels: a case-control study. Int Urol Nephrol 44(3):829-
839. 
38. Redal-Baigorri B, Rasmussen K, Heaf JG (2013). 
The use of absolute values improves performance 
of estimation formulae: a retrospective cross sectional 
study. BMC Nephrol 14: 271. 
39. Roberts RA, Laskin DL, Smith CV, Robertson FM, Allen EM, 
Doorn JA, Slikker W (2009). Nitrative and oxidative stress 
in toxicology and disease. Toxicol Sci 112(1):4-16. 
40. Roberts RA, Smith RA, Safe S, Szabo C, Tjalkens 
RB, Robertson FM (2010). Toxicological and 
pathophysiological roles of reactive oxygen and nitrogen 
species. Toxicology  276(2):85-94. 
41. Schieber M, Chandel NS (2014). ROS Function in Redox 
Signaling and Oxidative Stress. Curr Biol 24(10): 
R453-R462. 
42. Shaqman M, Ioannidou E, Burleson J, Hull D, Dongari-
Bagtzoglou A (2010). Periodontitis and inϐlammatory 
markers in transplant recipients. J Periodontol 81(5):666-
672. 
43. Thorman R, Lundahl J, Yucel-Lindberg T, Hylander B 
(2010). Inϐlammatory cytokines in saliva: early signs 
of metabolic disorders in chronic kidney disease. A 
controlled cross-sectional study. Oral Surg Oral Med Oral 
Pathol Oral Radiol Endod 110(5):597-604. 
44. Tomofuji T, Ekuni D, Irie K, Azuma T, Tamaki N, Maruyama 
T, Yamamoto T, Watanabe T, Morita M (2011) Relationships 
between periodontal inϐlammation, lipid peroxide and 
oxidative damage of multiple organs in rats. Biomed Res 
32(5):343-349.
45. Tsai J-P, Liou JH, Kao WT, Wang SC, Lian JD, Chang HR 
(2012). Increased Expression of Intranuclear Matrix 
Metalloproteinase 9 in Atrophic Renal Tubules Is 
Associated with Renal Fibrosis. PLoS ONE 7(10): e48164. 
46.  Wan C, Yuan G, Yang J, Sun Q, Zhang L, Zhang J, et al. (2014). 
MMP9 deϐiciency increased  the size of experimentally 
induced apical periodontitis. J Endod 40(5):658-664. 
47. Wehmeyer MM, Kshirsagar AV, Barros SP, Beck JD, Moss 
KL, Preisser JS, et al. (2013). A randomized controlled 
trial of intensive periodontal therapy on metabolic and 
inϐlammatory markers in patients With ESRD: results of 
an exploratory study. Am J Kidney Dis 61(3):450-458.
DALAI et al
